Literature DB >> 2076721

Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

C Wolfrom1, R Hepp, R Hartmann, H Breithaupt, G Henze.   

Abstract

The pharmacokinetics of methotrexate (MTX), 7-hydroxymethotrexate (7-OHMTX), 2,4-diaminomethylpteroic acid (APA), folinic acid, and 5-methyltetrahydrofolate (5-MTHF) have been studied during 21 high-dose MTX (HDMTX) infusions (5 g.m-2 in 24 h) with leucovorin (LCV) rescue, a component of the therapy of 5 children with acute lymphoblastic leukemia (ALL). The median steady-state concentration of MTX was 66 mumol.l-1. Three elimination half-lifes were determined for MTX: 1.8 h, 6.4 h and a terminal 15 h. The median systemic MTX clearance was 110 mg.m-2.min-1. The 7-OHMTX level increased during each infusion and a Cmax of 19 mumol.l-1 was achieved at the end. Its initial half-life was 5 h and the terminal half-life was 12 h. Thus, the peak serum concentration ratio of 7-OHMTX to MTX was reached 24 h after the end of the infusion at a median ratio of 8. The MTX metabolite APA was detected in concentrations less than 0.06 mumol.l-1. The median folinic acid level during rescue, 48 h after starting the infusion, was 7.0 mumol.l-1 and 18 h following the last dose of LCV it was 0.44 mumol.l-1, leading to ratios of folinic acid to MTX of 31 and 6, respectively. The median 5-MTHF level during rescue was 0.44 mumol.l-1 with a median ratio of 5-MTHF to MTX of 2. Twenty infusions with 48 h MTX levels of less than 0.5 mumol.l-1 were without marked toxicity. Only one patient with a 48 h MTX concentration of 5.5 mumol.l-1 and a ratio of 5-MTHF to MTX of 0.08 suffered from ulcerating mucositis and septicaemia despite increased and prolonged LCV rescue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076721     DOI: 10.1007/BF00315414

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  54 in total

1.  Accumulation of tetrahydrofolates in human plasma after leucovorin administration.

Authors:  M A Bunni; B M Rembiesa; D G Priest; E Sahovic; R Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Direct resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate using a bovine serum albumin high-performance liquid chromatographic chiral stationary phase coupled to an achiral phenyl column.

Authors:  I W Wainer; R M Stiffin
Journal:  J Chromatogr       Date:  1988-01-22

3.  A direct analysis of methotrexate, dichloromethotrexate and their 7-hydroxy metabolites in plasma by high pressure liquid chromatography.

Authors:  W P Tong; J L Wisnicki; J Horton; D B Ludlum
Journal:  Clin Chim Acta       Date:  1980-10-23       Impact factor: 3.786

4.  Exchange between parenteral and tissue folate in man.

Authors:  I Chanarin; J Perry
Journal:  Br J Haematol       Date:  1970-06       Impact factor: 6.998

5.  Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.

Authors:  H J Cohen; N Jaffe
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

6.  Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: a clinically directed laboratory study.

Authors:  D M Moccio; F M Sirotnak; L L Samuels; T Ahmed; A Yagoda; J I DeGraw; J R Piper
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

7.  In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells.

Authors:  G Fabre; L H Matherly; R Favre; J Catalin; J P Cano
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

8.  Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies.

Authors:  K Sasaki; J Tanaka; T Murakami; H Matuoka; T Fujimoto; H Taguchi
Journal:  Cancer Drug Deliv       Date:  1985

9.  Plasma methotrexate as determined by liquid chromatography, enzyme-inhibition assay, and radioimmunoassay after high-dose infusion.

Authors:  S K Howell; Y M Wang; R Hosoya; W W Sutow
Journal:  Clin Chem       Date:  1980-05       Impact factor: 8.327

10.  Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography.

Authors:  B Payet; G Fabre; N Tubiana; J P Cano
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more
  9 in total

1.  Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Authors:  Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Acute kidney injury, agranulocytosis, drug-induced liver injury, and posterior reversible encephalopathy syndrome caused by high-dose methotrexate-possible role of low activity ABC and SLC drug transporters.

Authors:  L Bielen; I Kralj; Ela Ćurčić; M Vodanović; A Boban; N Božina
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

3.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.

Authors:  Olivia S Beane; Louise E O Darling; Vera C Fonseca; Eric M Darling
Journal:  Stem Cell Rev Rep       Date:  2016-06       Impact factor: 5.739

6.  Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia.

Authors:  E Driehuis; N Oosterom; S G Heil; I B Muller; M Lin; S Kolders; G Jansen; R de Jonge; R Pieters; H Clevers; M M van den Heuvel-Eibrink
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

7.  Targeting TNF-α and NF-κB activation by bee venom: role in suppressing adjuvant induced arthritis and methotrexate hepatotoxicity in rats.

Authors:  Samar F Darwish; Wesam M El-Bakly; Hossam M Arafa; Ebtehal El-Demerdash
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

8.  Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.

Authors:  Natanja Oosterom; Robert de Jonge; Desiree E C Smith; Rob Pieters; Wim J E Tissing; Marta Fiocco; Bertrand D van Zelst; Marry M van den Heuvel-Eibrink; Sandra G Heil
Journal:  PLoS One       Date:  2019-09-17       Impact factor: 3.240

9.  The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.

Authors:  N Oosterom; M Fiocco; R Q H Kloos; I M van der Sluis; R Pieters; B D van Zelst; D E C Smith; M M van den Heuvel-Eibrink; R de Jonge; S G Heil
Journal:  BMC Cancer       Date:  2020-09-30       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.